| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |